Rabbit Recombinant Monoclonal Granzyme A antibody - conjugated to Biotin. Suitable for sELISA and reacts with Human samples.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
sELISA | |
---|---|
Human | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Abundant protease in the cytosolic granules of cytotoxic T-cells and NK-cells which activates caspase-independent pyroptosis when delivered into the target cell through the immunological synapse (PubMed:12819770, PubMed:32299851, PubMed:3257574, PubMed:3262682, PubMed:3263427). It cleaves after Lys or Arg (PubMed:12819770, PubMed:32299851). Once delivered into the target cell, acts by catalyzing cleavage of gasdermin-B (GSDMB), releasing the pore-forming moiety of GSDMB, thereby triggering pyroptosis and target cell death (PubMed:32299851, PubMed:34022140, PubMed:36157507, PubMed:36899106). Cleaves APEX1 after 'Lys-31' and destroys its oxidative repair activity (PubMed:12524539). Cleaves the nucleosome assembly protein SET after 'Lys-189', which disrupts its nucleosome assembly activity and allows the SET complex to translocate into the nucleus to nick and degrade the DNA (PubMed:11555662, PubMed:12628186, PubMed:16818237).
CTLA3, HFSP, GZMA, Granzyme A, CTL tryptase, Cytotoxic T-lymphocyte proteinase 1, Fragmentin-1, Granzyme-1, Hanukkah factor, H factor, HF
Rabbit Recombinant Monoclonal Granzyme A antibody - conjugated to Biotin. Suitable for sELISA and reacts with Human samples.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Granzyme A also known as CTLA3 or GZMA is a serine protease with a role in immune cell-mediated cytotoxicity. It has a molecular weight of approximately 27 kDa. This protein is primarily expressed in the granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Granzyme A gets released into the immunological synapse upon recognition of target cells by these immune cells facilitating the induction of target cell death.
Functions of Granzyme A extend to inducing apoptosis in target cells alongside its role in promoting inflammation. It operates independent of caspases and directly cleaves substrates in the cell to induce cell death making it different from the related Granzyme B. As part of the granzyme-perforin complex it enters target cells via perforin-created pores mediates reactions leading to substrate degradation and promotes DNA damage.
Granzyme A gets involved in the granule exocytosis pathway which constitutes an important mechanism for CTLs and NK cells to kill infected or cancerous cells. The protein is also linked to the inflammatory response pathways where it can interact with other serine proteases. Related proteins like perforin and Granzyme B also engage in these pathways and they collectively work to trigger apoptosis and modulate immune responses.
Impairments or dysregulation of Granzyme A function can contribute to autoimmune diseases and certain viral infections. Autoimmune diseases such as lupus may demonstrate altered levels or activity of Granzyme A associated with tissue damage and inflammation. During viral infections Granzyme A in conjunction with perforin and Granzyme B aids in eliminating infected cells but alterations in this balance could lead to ineffective immune responses or excessive tissue damage.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com